Elevate your local knowledge
Sign up for the iNFOnews newsletter today!

WHITEHOUSE STATION, N.J. – Drugmaker Merck & Co. says its second-quarter profit fell by half because of generic competition cutting into sales and acquisition and other charges.
The maker of blockbuster diabetes pill Januvia and Gardasil, a vaccine against sexually transmitted cancers, says second-quarter net income was $906 million, or 30 cents per share, down from $1.79 billion, or 58 cents per share, a year earlier.
Excluding one-time items, the world’s third-biggest drugmaker says adjusted net income was $2.53 billion, or 84 cents per share. Analysts surveyed by FactSet expected 82 cents.
Merck, based in Whitehouse Station, N.J., says revenue totalled $11.01 billion, down 11 per cent. Analysts expected slightly higher sales of $11.24 billion.
The company backed its previous 2013 profit forecast for earnings per share of $1.84 to $2.05, excluding one-time items.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Want to share your thoughts, add context, or connect with others in your community?
You must be logged in to post a comment.